Get started
Author

Prashanth Hari Dass

Observed names: Dass, P. Hari, Prashanth hari dass
Observed institutions: Churchill Hospital, Waikato Hospital, University of Oxford, Rotorua Hospital, Waikato District Health Board, Health New Zealand
ORCID: 0000-0003-4832-0639
Observed ORCID: 0000-0003-4832-0639
OpenAlex ID: A5038301634
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
2022 · Elizabeth J Davis, Juan Martin-Liberal, et al. · Journal for ImmunoTherapy of Cancer · 82
PDF
Ketogenic metabolic therapy in conjunction with standard treatment for glioblastoma: A case report
2024 · Matthew Phillips, Ziad Thotathil, et al. · Oncology Letters · 21
PDF
Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients
2017 · Matteo Morotti, Prashanth Hari Dass, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 8
Tumour Lysis Syndrome in Occult Breast Cancer Treated With Letrozole – A Rare Occurrence. A Case Report and Review
2021 · George E Watkinson, Prashanth Hari Dass · Breast Cancer Basic and Clinical Research · 6
Parathyroid Hormone–Related Peptide Secretion From a Pancreatic Neuroendocrine Tumor: A Rare Case Report of Severe Hypercalcemia
2024 · Erin Foley, Prashanth Hari Dass, et al. · AACE Clinical Case Reports · 3
PDF
Aggressive Digital Papillary Adenocarcinoma
2018 · Pragya Attri, Prashanth Hari Dass · Journal of Rare Disorders: Diagnosis & Therapy · 3
PDF
Testicular cancer: a 13‐year retrospective review of ethnic disparities in the Waikato region, New Zealand
2019 · Prashanth Hari Dass, Michael B. Jameson · Internal Medicine Journal · 2
A Review of Squamous Cell Vulvar Cancers in Waikato Region, New Zealand.
2016 · Prashanth Hari Dass, Marion Kuper-Hommel · Journal of Clinical Oncology · 2
Proton pump inhibition to prevent delayed chemotherapy-induced nausea and vomiting in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy: a phase II, randomised double-blind crossover trial (PantoCIN)
2025 · Navin Wewala, Yujin Kim, et al. · Supportive Care in Cancer · 1
A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC).
2024 · Dan Liu, Lin Shen, et al. · Journal of Clinical Oncology · 1
A Review of Squamous Cell Vulvar Cancers in Waikato Region, New Zealand
2015 · Prashanth Hari Dass · PubMed · 1
Immunotherapy for dMMR Colorectal Cancer – Early Outcomes & Equity Implications from a Single Centre New Zealand Cohort
2026 · joshua kirkpatrick, ann-maree murphy, et al.
Survival Outcomes by Cancer Type & Characteristics of Patients Diagnosed with Brain Metastases in Te Whatu Ora Lakes
2026 · joyee gui, ashford taylor, et al.
Pancreatic Cancer Outcomes at Te Whatu Ora Lakes
2026 · Mclean, Theresa, Prashanth hari dass
Process of development of decentralised clinical trial methodology for cancer clinical trials in Aotearoa New Zealand
2024 · Nicola Lawrence, Bobbi Laing, et al. · New Zealand Medical Journal
PDF
Case series: Outcomes of immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinoma in Lakes and Waikato region.
2024 · Ahrabie Yogarajah, Alistair Wickham, et al. · Journal of Clinical Oncology
PDF
Health disparities in New Zealand Māori with pancreatic cancer at Lakes District health board.
2021 · Laura Camburn, Prashanth Hari Dass · Journal of Clinical Oncology
Patterns of presentation among New Zealand Māori with pancreatic cancer at Lakes District Health Board.
2021 · Laura Camburn, Prashanth Hari Dass · Journal of Clinical Oncology
A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours
2018 · Wilson, Richard, Dass, P. Hari, et al. · Research Portal (Queen's University Belfast)
A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of the dual MET kinase/OCT2 inhibitor, OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies.
2018 · Elizabeth Ruth Plummer, Martijn P. Lolkema, et al. · Journal of Clinical Oncology
Volunteering in medical oncology
2018 · Prashanth Hari Dass · Journal of Clinical and Molecular Medicine
PDF
Testicular cancer ethnic disparities in the Waikato region, New Zealand.
2016 · Prashanth Hari Dass, Michael B. Jameson · Journal of Clinical Oncology
Post lumbar puncture leg weakness mimicking cauda equina syndrome.
2015 · Prashanth Hari Dass · PubMed
Works count: 26
Citation count: 130
H-index: 4
I10-index: 2
Year
Topic
Type